tiprankstipranks
Vincent Medical Holdings Limited (HK:1612)
:1612
Hong Kong Market

Vincent Medical Holdings Limited (1612) AI Stock Analysis

1 Followers

Top Page

HK:1612

Vincent Medical Holdings Limited

(1612)

Select Model
Select Model
Select Model
Outperform 71 (OpenAI - 5.2)
Rating:71Outperform
Price Target:
HK$1.00
▲(20.48% Upside)
Action:ReiteratedDate:01/29/26
Overall score is driven primarily by solid financial positioning and growth with low leverage, plus an attractive valuation (low P/E and ~4.23% yield). These positives are partially offset by weak 2024 cash generation (free cash flow at zero) and somewhat stretched near-term technical conditions (RSI ~73).
Positive Factors
Revenue growth and market demand
Consistent double-digit revenue growth in 2024 reflects sustained demand for its respiratory and critical-care devices and validates its commercial reach. Durable growth supports capacity to invest in R&D, expand distribution, and scale production over the next several quarters.
Negative Factors
Weak cash flow conversion
A collapse of free cash flow and zero OCF-to-net-income conversion in 2024 signals difficulty turning accounting profits into cash. This undermines the firm’s ability to self-fund capex, R&D, dividends, or M&A without relying on external financing over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and market demand
Consistent double-digit revenue growth in 2024 reflects sustained demand for its respiratory and critical-care devices and validates its commercial reach. Durable growth supports capacity to invest in R&D, expand distribution, and scale production over the next several quarters.
Read all positive factors

Vincent Medical Holdings Limited (1612) vs. iShares MSCI Hong Kong ETF (EWH)

Vincent Medical Holdings Limited Business Overview & Revenue Model

Company Description
Vincent Medical Holdings Limited, an investment holding company, researches, develops, manufactures, markets, and sells medical devices. It operates in two segments, Original Equipment Manufacturing (OEM) and Original Brand Manufacturing. The comp...
How the Company Makes Money
Vincent Medical Holdings generates revenue primarily through the sale of its medical devices and equipment to healthcare providers, hospitals, and distributors. The company benefits from a diversified revenue model that includes direct sales, part...

Vincent Medical Holdings Limited Financial Statement Overview

Summary
Good revenue growth (~11.56% in 2024) and solid balance sheet strength (equity ratio ~62.93%, low debt-to-equity ~0.17). Profitability is reasonable (gross margin ~32.48%, net margin ~8.64%), but earnings/EBIT have shown volatility and cash conversion weakened materially with free cash flow falling to zero in 2024.
Income Statement
70
Positive
Balance Sheet
75
Positive
Cash Flow
60
Neutral
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue869.70M800.96M717.97M629.24M777.72M1.16B
Gross Profit299.82M259.99M240.39M147.83M243.83M478.79M
EBITDA137.82M100.00M104.43M29.95M114.55M329.25M
Net Income87.51M69.17M57.27M-17.40M60.70M216.87M
Balance Sheet
Total Assets1.08B919.68M786.61M726.70M846.15M946.87M
Cash, Cash Equivalents and Short-Term Investments204.33M173.44M175.78M159.34M173.17M169.07M
Total Debt162.80M99.65M37.38M60.39M62.96M84.69M
Total Liabilities452.36M336.33M243.52M228.09M245.72M341.69M
Stockholders Equity623.44M578.55M541.84M498.01M598.36M611.56M
Cash Flow
Free Cash Flow-46.94M-26.52M61.28M57.67M94.48M142.19M
Operating Cash Flow84.23M73.48M124.97M76.27M119.43M204.77M
Investing Cash Flow-137.85M-98.81M-62.37M-18.61M-20.69M-132.19M
Financing Cash Flow89.10M26.39M-45.37M-67.84M-101.16M10.13M

Vincent Medical Holdings Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.83
Price Trends
50DMA
0.97
Negative
100DMA
0.91
Positive
200DMA
0.87
Positive
Market Momentum
MACD
-0.02
Positive
RSI
42.94
Neutral
STOCH
56.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1612, the sentiment is Negative. The current price of 0.83 is below the 20-day moving average (MA) of 0.95, below the 50-day MA of 0.97, and below the 200-day MA of 0.87, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.94 is Neutral, neither overbought nor oversold. The STOCH value of 56.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1612.

Vincent Medical Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
HK$606.52M5.1316.21%4.94%17.93%36.82%
53
Neutral
HK$965.82M-1.91-30.05%-8.56%-14.84%
52
Neutral
HK$410.07M12.164.40%-2.77%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
44
Neutral
HK$547.05M-2.91-21.93%11.43%4.88%
41
Neutral
HK$724.37M-4.03-9.19%-30.60%28.61%
40
Underperform
HK$230.63M10.43-34.76%6.10%-115.12%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1612
Vincent Medical Holdings Limited
0.92
0.54
142.11%
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
2.00
-0.90
-31.03%
HK:2216
Broncus Holding Corp.
1.37
0.42
44.21%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.10
0.03
41.43%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.19
0.25
12.89%
HK:6118
Austar Lifesciences Ltd.
0.80
0.02
2.56%

Vincent Medical Holdings Limited Corporate Events

Vincent Medical Flags Sharp Profit Rise on Expanded Imaging Disposables Business
Jan 27, 2026
Vincent Medical Holdings Limited has issued a positive profit alert, indicating that unaudited consolidated profit attributable to owners for the year ended 31 December 2025 is expected to be not less than HK$100 million, up from HK$69.2 million a...
Vincent Medical Renews Key Lease and Service Agreements
Dec 15, 2025
Vincent Medical Holdings Limited has announced the renewal of its lease agreements with VRDL and VRDG for properties in Hong Kong and the PRC, extending the lease term from January 2026 to December 2027. Additionally, the company has renewed its a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 29, 2026